Skip to main content

Hepatic Disorders

Hepatitis C Criteria  

Mavyret is available with NO prior authorization and is the preferred direct acting antiviral (DAA) for the treatment of chronic hepatitis C virus. Use of an alternative regimen for the treatment of HCV requires a patient-specific, clinically significant reasoning why the preferred DAA is not appropriate for the member. Mavyret™ (glecaprevir/ pibrentasvir) oral pellets are covered for pediatric patients 3 to 11 years of age requiring that dosage form.

Hepatitis C Therapy Forms:

Hepatitis C Therapy Intent to Treat Contract 
Hepatitis C Therapy Pharmacy Agreement 
Hepatitis C Therapy Continuation

Last Modified on May 07, 2025
Back to Top